TP53 and acute myeloid leukemia: In brief, targeted treatments, including those targeting mutant p53, along with immunotherapeutic agents, have yielded vastly different response rates in TP53mut AML patients, as seen in Table 1 [53,54,55,56,57,58,64,65,66,67,71,72,80,84,87,90,94,95,96,97,104].